SB 1042: Mental Health Emerging Therapies Pilot Program; Office of Wellness and Resilience; Appropriation
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2025-03-17
Current Status:
Failed
(2026-04-02: Received notice of the discharge of all House Conferees (Hse. Com. No. 457).)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Final Decking
Enacted
Establishes a two-year Mental Health Emerging Therapies Pilot Program within the Office of Wellness and Resilience. Appropriates funds. Effective 7/1/3000. (HD1)
Establishes and appropriates moneys for a Mental Health Emerging Therapies Special Fund, to be administered by the Department of Health. Requires annual reports to the Legislature. Effective 12/31/2050. (SD1)
Establishes and appropriates moneys for a mental health emerging therapies special fund, to be administered by the Department of Health. Requires annual reports to the Legislature.
|
THE SENATE |
S.B. NO. |
1042 |
|
THIRTY-THIRD LEGISLATURE, 2025 |
S.D. 1 |
|
|
STATE OF HAWAII |
H.D. 1 |
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO MENTAL HEALTH.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
The legislature further finds that the United States Food and Drug Administration has granted breakthrough therapy designation to emerging treatments, such as MDMA-assisted therapy for PTSD and psilocybin therapy for treatment-resistant depression, recognizing their potential to offer rapid and substantial improvements over existing treatments. These therapies, when administered in clinical settings with the proper safeguards, have demonstrated promising results in reducing symptoms of PTSD and suicidal ideation, particularly among veterans who have not responded to conventional treatments.
The legislature also finds that establishing a mental health emerging therapies pilot project within the office of wellness and resilience, using private moneys to match state funds, will enable the State to assess the feasibility, effectiveness, and accessibility of these cutting-edge therapies for individuals in Hawaii who could stand to benefit the most. By investing in evidence-based emerging therapies through the pilot project, the State can lead the way in expanding mental health care options, improving health outcomes, and reducing veteran suicide rates.
Accordingly, the purpose of this Act is to establish and appropriate funds for a two-year mental health emerging therapies pilot program within the office of wellness and resilience.
SECTION 2. (a) There is established a two-year mental health emerging therapies pilot program within the office of wellness and resilience to support clinical research and the development of emerging therapies for the treatment of mental health and behavioral health disorders.
(b) The pilot program may:
(1) Establish partnerships with public and private stakeholders, such as public agencies, academic institutions, health care providers, or any other as the office of wellness and resilience may deem appropriate;
(2) Fund phase three clinical trials of treatments or therapies that have received a breakthrough-therapy designation from the United States Food and Drug Administration, investor-initiated clinical trails, or other clinical trials, including trials to:
(A) Inform optimal methods of treatment delivery;
(B) Inform transdiagnostic safety and efficacy; and
(C) Inform patient access, patient support services, and real world data collection and analysis;
(3) Fund education and training opportunities for mental health professionals;
(4) Support public education and harm reduction;
(5) Fund implementation studies, including research and analyses of best practices, cost effectiveness, and methods to reduce treatment costs; and
(6) Provide recommendations for expanding patient access, patient support services, and other means by which those with mental health and behavioral health needs may access emerging therapies.
(c) The office of wellness and resilience may contract with a third party to administer funding under the mental health emerging therapies pilot program.
(d) The office of wellness and resilience may adopt rules without regard to chapter 91, Hawaii Revised Statutes, to administer the pilot program.
(e) The office of wellness and resilience shall submit a report of its activities to the legislature no later than twenty days prior to the convening of the regular sessions of 2026 and 2027. Each report shall include but not be limited to:
(1) The studies funded and efforts supported by the mental health emerging therapies pilot program in the previous year;
(2) Any findings and recommendations; and
(3) Any proposed legislation.
(f) The mental health emerging therapies pilot program shall cease to exist on June 30, 2027.
(g) For the purposes of this Act, "emerging therapies" means any psychedelic or entactogenic compound or mixture that is:
(1) Undergoing clinical trials regulated by the United States Food and Drug Administration for the treatment of mental health or behavioral health conditions;
(2) Approved by the United States Food and Drug administration for marketing in interstate commerce; or
(3) Approved for medical use under state law.
SECTION 3. There is appropriated out of the general revenues of the State of Hawaii the sum of $ or so much thereof as may be necessary for fiscal year 2025-2026 and the same sum or so much thereof as may be necessary for fiscal year 2026-2027 for the mental health emerging therapies pilot program.
The sums appropriated shall be expended by the office of wellness and resilience for the purposes of this Act.
SECTION 4. This Act shall take effect on July 1, 3000.
Report Title:
Mental Health Emerging Therapies Pilot Program; Office of Wellness and Resilience; Appropriation
Description:
Establishes a two-year Mental Health Emerging Therapies Pilot Program within the Office of Wellness and Resilience. Appropriates funds. Effective 7/1/3000. (HD1)
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
|
THE SENATE |
S.B. NO. |
1042 |
|
THIRTY-THIRD LEGISLATURE, 2025 |
S.D. 1 |
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO MENTAL HEALTH.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
"§321- Mental health emerging therapies special fund. (a) There is established in the state treasury the mental health emerging therapies special fund to be administered by the department of health. The following moneys shall be deposited into the fund:
(1) Appropriations by the legislature to the special fund; and
(2) Gifts, donations, and grants from public agencies and private persons.
All interest earned or accrued on moneys deposited into the special fund shall become part of the special fund.
(b) Moneys in the special fund shall be expended to support clinical research and the development of emerging therapies for the treatment of mental health and behavioral health disorders. Among other purposes, the moneys may be used for:
(1) Establishing public-private partnerships to jointly fund phase three clinical trials of United States Food and Drug Administration breakthrough therapies;
(2) Funding investor-initiated clinical trials, including trials to:
(A) Inform optimal methods of treatment delivery; and
(B) Inform transdiagnostic safety and efficacy;
(3) Establishing compassionate use programs, including data collection and analysis;
(4) Funding education and training opportunities for mental health professionals;
(5) Supporting public education and harm reduction;
(6) Developing patient access pilot programs, including real-world data collection and analysis;
(7) Establishing community programs to provide long-term patient support services; and
(8) Funding implementation studies, including research and analyses of best practices, cost effectiveness, and methods to reduce treatment costs.
(c) The department shall adopt rules pursuant to chapter 91 for the administration of the mental health emerging therapies special fund.
(d) The department shall submit to the legislature no later than twenty days prior to the convening of each regular session, beginning with the regular session of 2026, a report of:
(1) The studies funded and efforts supported by the mental health emerging therapies special fund in the previous year;
(2) The department's findings and recommendations; and
(3) Any proposed legislation.
(e) For the purposes of this section:
"Compassionate use" means treating patients suffering from terminal or life-threatening conditions, including treatment‑resistant mental health conditions under either the federal Right to Try Act, Public Law 115-176, or the Food and Drug Administration Expanded Access program (21 U.S.C. 360bbb(b)).
"Emerging therapies" means any psychedelic or entactogenic compound or mixture that is either:
(1) Undergoing clinical trials regulated by the United States Food and Drug Administration for the treatment of a mental or behavioral health condition;
(2) Approved by the United States Food and Drug Administration for marketing in interstate commerce; or
(3) Approved for medical use under Hawaii law.
"United States Food and Drug Administration breakthrough therapies" means investigational drugs that have been granted breakthrough therapy designation by the United States Food and Drug Administration under section 506(a) of the Food, Drug, and Cosmetic Act (21 U.S.C. 356(a))."
SECTION 2. There is appropriated out of the general revenues of the State of Hawaii the sum of $ or so much thereof as may be necessary for fiscal year 2025-2026 and the same sum or so much thereof as may be necessary for fiscal year 2026-2027 for deposit into the mental health emerging therapies special fund.
SECTION 3. There is appropriated out of the mental health emerging therapies special fund the sum of $ or so much thereof as may be necessary for fiscal year 2025-2026 and the same sum or so much thereof as may be necessary for fiscal year 2026-2027 for supporting clinical research and the use of emerging therapies for treating mental and behavioral health disorders.
The sums appropriated shall be expended by the department of health for the purposes of this Act.
SECTION 4. New statutory material is underscored.
SECTION 5. This Act shall take effect on December 31, 2050.
Report Title:
DOH; Mental Health; Emerging Therapies, Breakthrough Therapies; Special Fund; Reports; Appropriations
Description:
Establishes and appropriates moneys for a Mental Health Emerging Therapies Special Fund, to be administered by the Department of Health. Requires annual reports to the Legislature. Effective 12/31/2050. (SD1)
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
|
THE SENATE |
S.B. NO. |
1042 |
|
THIRTY-THIRD LEGISLATURE, 2025 |
|
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
relating to mental health.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
"§321- Mental health emerging therapies special fund. (a) There is established in the state treasury the mental health emerging therapies special fund to be administered by the department of health. The following moneys shall be deposited into the fund:
(1) Appropriations by the legislature to the special fund; and
(2) Gifts, donations, and grants from public agencies and private persons.
All interest earned or accrued on moneys deposited into the special fund shall become part of the special fund.
(b) Moneys in the special fund shall be expended to support clinical research and the development of emerging therapies for the treatment of mental health and behavioral health disorders. Among other purposes, the moneys may be used for:
(1) Establishing public-private partnerships to jointly fund phase three clinical trials of United States Food and Drug Administration breakthrough therapies;
(2) Funding investor-initiated clinical trials, including trials to:
(A) Inform optimal methods of treatment delivery; and
(B) Inform transdiagnostic safety and efficacy;
(3) Establishing compassionate use programs, including data collection and analysis;
(4) Funding education and training opportunities for mental health professionals;
(5) Supporting public education and harm reduction;
(6) Developing patient access pilot programs, including real-world data collection and analysis;
(7) Establishing community programs to provide long-term patient support services; and
(8) Funding implementation studies, including research and analyses of best practices, cost effectiveness, and methods to reduce treatment costs.
(c) The department shall adopt rules pursuant to chapter 91 for the administration of the mental health emerging therapies special fund.
(d) The department shall submit to the legislature no later than twenty days prior to the convening of each regular session, beginning with the regular session of 2026, a report of:
(1) The studies funded and efforts supported by the mental health emerging therapies special fund in the previous year;
(2) The department's findings and recommendations; and
(3) Any proposed legislation.
(e) For the purposes of this section:
"Compassionate use" means treating patients suffering from terminal or life-threatening conditions, including treatment‑resistant mental health conditions under either the federal Right to Try Act (P.L. 115-176) or the Food and Drug Administration Expanded Access program (21 United States Code section 360bbb(b)).
"Emerging therapies" means any psychedelic or entactogenic compound or mixture that is either:
(1) Undergoing clinical trials regulated by the United States Food and Drug Administration for the treatment of a mental or behavioral health condition;
(2) Approved by the United States Food and Drug Administration for marketing in interstate commerce; or
(3) Approved for medical use under Hawaii law.
"United States Food and Drug Administration breakthrough therapies" means investigational drugs that have been granted breakthrough therapy designation by the United States Food and Drug Administration under section 506(a) of the Food, Drug, and Cosmetic Act (21 United States Code section 356(a))."
SECTION 2. There is appropriated out of the general revenues of the State of Hawaii the sum of $ or so much thereof as may be necessary for fiscal year 2025-2026 and the same sum or so much thereof as may be necessary for fiscal year 2026-2027 for deposit into the mental health emerging therapies special fund.
SECTION 3. There is appropriated out of the mental health emerging therapies special fund the sum of $ or so much thereof as may be necessary for fiscal year 2025-2026 and the same sum or so much thereof as may be necessary for fiscal year 2026-2027 for supporting clinical research and the use of emerging therapies for treating mental and behavioral health disorders.
The sums appropriated shall be expended by the department of health for the purposes of this Act.
SECTION 4. New statutory material is underscored.
SECTION 5. This Act shall take effect on July 1, 2025.
|
INTRODUCED BY: |
_____________________________ |
|
|
|
Report Title:
DHS; Mental Health; Emerging Therapies, Breakthrough Therapies; Special Fund; Reports; Appropriation
Description:
Establishes and appropriates moneys for a mental health emerging therapies special fund, to be administered by the Department of Health. Requires annual reports to the Legislature.
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
|
Date
|
Status
|
|---|---|
| Apr 2, 2026 | Received notice of the discharge of all House Conferees (Hse. Com. No. 457). |
| Apr 1, 2026 | House Conferee(s) discharged. |
| Mar 20, 2026 | Received notice of all Senate conferees being discharged (Sen. Com. No. 409). |
| Mar 20, 2026 | Senate Conferee(s) discharged. |
| Dec 8, 2025 | Carried over to 2026 Regular Session. |
| Apr 25, 2025 | Conference committee meeting to reconvene on 04-25-25 5:20 PM; Conference Room 329. |
| Apr 24, 2025 | Conference committee meeting scheduled for 04-25-25 3:15PM; Conference Room 329. |
| Apr 21, 2025 | Received notice of Senate conferees (Sen. Com. No. 848). |
| Apr 21, 2025 | Senate Conferees Appointed: San Buenaventura Chair; Lee, C. Co-Chair; Hashimoto, Fevella. |
| Apr 21, 2025 | Received notice of appointment of House conferees (Hse. Com. No. 754). |
| Apr 17, 2025 | House Conferees Appointed: Takayama, Takenouchi Co-Chairs; Alcos. |
| Apr 10, 2025 | Received notice of disagreement (Sen. Com. No. 779). |
| Apr 10, 2025 | Senate disagrees with House amendments. |
| Apr 10, 2025 | Received from House (Hse. Com. No. 668). |
| Apr 8, 2025 | Passed Third Reading with none voting aye with reservations; Representative(s) Kila, Kitagawa, Lamosao, Matayoshi, Pierick voting no (5) and Representative(s) Cochran, Marten excused (2). Transmitted to Senate. |
| Apr 4, 2025 | Reported from FIN (Stand. Com. Rep. No. 2011), recommending passage on Third Reading. |
| Apr 2, 2025 | The committee on FIN recommend that the measure be PASSED, UNAMENDED. The votes were as follows: 15 Ayes: Representative(s) Yamashita, Takenouchi, Grandinetti, Holt, Hussey, Keohokapu-Lee Loy, Kitagawa, Kusch, Lamosao, Lee, M., Miyake, Morikawa, Templo, Alcos, Reyes Oda; Ayes with reservations: none; Noes: none; and Excused: none. |
| Mar 31, 2025 | Bill scheduled to be heard by FIN on Wednesday, 04-02-25 3:30PM in House conference room 308 VIA VIDEOCONFERENCE. |
| Mar 18, 2025 | Passed Second Reading as amended in HD 1 and referred to the committee(s) on FIN with none voting aye with reservations; Representative(s) Pierick voting no (1) and Representative(s) Cochran, Ward excused (2). |
| Mar 18, 2025 | Reported from HLT (Stand. Com. Rep. No. 1312) as amended in HD 1, recommending passage on Second Reading and referral to FIN. |
| Mar 14, 2025 | The committee on HLT recommend that the measure be PASSED, WITH AMENDMENTS. The votes were as follows: 9 Ayes: Representative(s) Takayama, Keohokapu-Lee Loy, Amato, Chun, Marten, Olds, Takenouchi, Alcos, Garcia; Ayes with reservations: none; 0 Noes: none; and 0 Excused: none. |
| Mar 11, 2025 | Bill scheduled to be heard by HLT on Friday, 03-14-25 9:00AM in House conference room 329 VIA VIDEOCONFERENCE. |
| Mar 4, 2025 | Referred to HLT, FIN, referral sheet 18 |
| Mar 4, 2025 | Pass First Reading |
| Feb 28, 2025 | Received from Senate (Sen. Com. No. 50) in amended form (SD 1). |
| Feb 28, 2025 | Report Adopted; Passed Third Reading. Ayes, 22; Aye(s) with reservations: Senator(s) McKelvey. Noes, 1 (Senator(s) Awa). Excused, 2 (Senator(s) Fukunaga, Kidani). Transmitted to House. |
| Feb 27, 2025 | One Day Notice 02-28-25. |
| Feb 27, 2025 | Reported from WAM (Stand. Com. Rep. No. 782) with recommendation of passage on Third Reading. |
| Feb 19, 2025 | The committee(s) on WAM recommend(s) that the measure be PASSED, UNAMENDED. The votes in WAM were as follows: 13 Aye(s): Senator(s) Dela Cruz, Moriwaki, Aquino, DeCoite, Elefante, Hashimoto, Inouye, Kanuha, Kidani, Kim, Lee, C., Wakai, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none. |
| Feb 14, 2025 | The committee(s) on WAM will hold a public decision making on 02-19-25 10:02AM; Conference Room 211 & Videoconference. |
| Feb 14, 2025 | Report adopted; Passed Second Reading, as amended (SD 1) and referred to WAM. |
| Feb 14, 2025 | Reported from HHS (Stand. Com. Rep. No. 625) with recommendation of passage on Second Reading, as amended (SD 1) and referral to WAM. |
| Feb 12, 2025 | The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, Aquino, Hashimoto, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none. |
| Feb 7, 2025 | The committee(s) on HHS has scheduled a public hearing on 02-12-25 1:00PM; Conference Room 225 & Videoconference. |
| Jan 23, 2025 | Referred to HHS, WAM. |
| Jan 21, 2025 | Passed First Reading. |
| Jan 17, 2025 | Introduced. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Apr 8, 2025 | Third Reading | House Floor |
Passed |
|
| Apr 2, 2025 | The committee on FIN recommend that the measure be PASSED, UNAMENDED | House Standing Committee on Finance |
Passed |
|
| Mar 14, 2025 | The committee on HLT recommend that the measure be PASSED, WITH AMENDMENTS | House Standing Committee on Health |
Passed |
|
| Feb 28, 2025 | Third Reading | Senate Floor |
Passed |
|
| Feb 19, 2025 | The committee(s) on WAM recommend(s) that the measure be PASSED, UNAMENDED | Senate Standing Committee on Ways and Means |
Passed |
|
| Feb 12, 2025 | The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS | Senate Standing Committee on Health and Human Services |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Aloha Integrative Mental Health | ** Support | |
| Aloha Green Apothecary | *** Support | Apr 2, 2025 |
| Aloha Green Holdings Inc. | *** Support | Feb 12, 2025 |
| Aloha Integrative Mental Health | ** Support | |
| Beyond Mental Health | ** Support | |
| Boston University | *** Support | Feb 12, 2025 |
| Center for Healing & Transformation LLC | ** Support | |
| Center for Healing & Transformation LLC | *** Support | Feb 12, 2025 |
| Centered Hawaii, LLC | *** Support | Feb 19, 2025 |
| Clarity Project | *** Support | Apr 2, 2025 |
| Clarity Project | ** Support | |
| Hawaii Health & Harm Reduction Center | ** Support | |
| Hawaiʻi Workers Center | *** Support | Feb 12, 2025 |
| Honolulu Psychotherapy | ** Support | |
| John A. Burns School of Medicine (JABSOM) | *** Support | Apr 2, 2025 |
| Ke Kani o ka Lani | *** Support | Apr 2, 2025 |
| Maui Breakthrough Collaborative | *** Support | Apr 2, 2025 |
| Maui Breakthrough Collaborative (MBC) | *** Support | Feb 12, 2025 |
| MindWave Medicine | ** Support | |
| NPSYT | *** Support | Feb 12, 2025 |
| NPSYT, PLLC | *** Support | Apr 2, 2025 |
| Office of Wellness and Resilience | ** Support | |
| Office of Wellness and Resilience, Office of the Governor | *** Support | Apr 2, 2025 |
| reason for hope | ** Support | |
| Reason for Hope | *** Support | Apr 2, 2025 |
| Sierra Club of Hawaiʻi | *** Support | Feb 12, 2025 |
| The Order of the New Eleusis | *** Support | Apr 2, 2025 |
| Transcend Integration | ** Support | |
| Trueself Therapy, LLC | *** Support | Feb 12, 2025 |
| Veteran Mental Health Leadership Coalition | ** Support | |
| Veteran Mental Health Leadership Coalition | ** Support | |
| Veteran Mental Health Leadership Coalition | ** Support | |
| Veteran Mental Health Leadership Coalition | *** Support | Apr 2, 2025 |
| Veterans Exploring Treatment Solutions | ** Support | |
| Veterans Mental Health Leadership Coalition | *** Support | Feb 12, 2025 |
STAND. COM. REP. NO. 2011
Honolulu, Hawaii
, 2025
RE: S.B. No. 1042
S.D. 1
H.D. 1
Honorable Nadine K. Nakamura
Speaker, House of Representatives
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Madame:
Your Committee on Finance, to which was referred S.B. No. 1042, S.D. 1, H.D. 1, entitled:
"A BILL FOR AN ACT RELATING TO MENTAL HEALTH,"
begs leave to report as follows:
As affirmed by the record of votes of the members of your Committee on Finance that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1042, S.D. 1, H.D. 1, and recommends that it pass Third Reading.
Respectfully submitted on behalf of the members of the Committee on Finance,
|
|
|
____________________________ KYLE T. YAMASHITA, Chair |
|
|
|
|
STAND. COM. REP. NO. 1312
Honolulu, Hawaii
, 2025
RE: S.B. No. 1042
S.D. 1
H.D. 1
Honorable Nadine K. Nakamura
Speaker, House of Representatives
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Madame:
Your Committee on Health, to which was referred S.B. No. 1042, S.D. 1, entitled:
"A BILL FOR AN ACT RELATING TO MENTAL HEALTH,"
begs leave to report as follows:
The purpose of this measure is to establish and appropriate funds for the Mental Health Emerging Therapies Special Fund.
Your Committee received testimony in support of this measure from the Office of Wellness and Resilience; Beyond Mental Health; Aloha Integrative Mental Health; MindWave Medicine; Clarity Project; Veteran Mental Health Leadership Coalition; Reason for Hope; Veterans Exploring Treatment Solutions; Hawaii Health & Harm Reduction Center; and numerous individuals. Your Committee received comments on this measure from the Department of Budget and Finance and Department of the Attorney General.
Your Committee finds that there are a significant number of individuals, including a disproportionate number of veterans, who suffer from treatment-resistant depression and post-traumatic stress disorder. Your Committee further finds that the United States Food and Drug Administration has granted breakthrough therapy designation to emerging treatments, including psilocybin therapy and MDMA-assisted therapy, for treatment of various mental health and behavioral health disorders including addiction, treatment-resistant depression, eating disorders, and post-traumatic stress disorder.
Your Committee believes that there is significant value in exploring the use of these emerging therapies, which have demonstrated promising results when administered in clinical settings. However, your Committee believes that establishing a pilot program, rather than the special fund proposed by this measure, may be a more appropriate mechanism to allow the State to assess the feasibility, effectiveness, and accessibility of these emerging therapies.
Accordingly, your Committee has amended this measure by:
(1) Deleting the substantive contents of this measure and inserting language requiring the Office of Wellness and Resilience to conduct a two-year Mental Health Emerging Therapies Pilot Program to support clinical research and the development of emerging therapies for the treatment of mental health and behavioral health disorders and report to the Legislature;
(2) Inserting an unspecified appropriation amount for the Mental Health Emerging Therapies Pilot Program;
(3) Changing the effective date to July 1, 3000, to encourage further discussion; and
(4) Making technical, nonsubstantive amendments for the purposes of clarity, consistency, and style.
Your Committee respectfully requests your Committee on Finance, should it deliberate on this measure, to consider an appropriation amount of $1,000,000.
As affirmed by the record of votes of the members of your Committee on Health that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1042, S.D. 1, as amended herein, and recommends that it pass Second Reading in the form attached hereto as S.B. No. 1042, S.D. 1, H.D. 1, and be referred to your Committee on Finance.
Respectfully submitted on behalf of the members of the Committee on Health,
|
|
|
____________________________ GREGG TAKAYAMA, Chair |
|
|
|
|
STAND. COM. REP. NO. 782
Honolulu, Hawaii
RE: S.B. No. 1042
S.D. 1
Honorable Ronald D. Kouchi
President of the Senate
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Sir:
Your Committee on Ways and Means, to which was referred S.B. No. 1042, S.D. 1, entitled:
"A BILL FOR AN ACT RELATING TO MENTAL HEALTH,"
begs leave to report as follows:
The purpose and intent of this measure is to establish and appropriate moneys for a Mental Health Emerging Therapies Special Fund to be administered by the Department of Health.
Your Committee received written comments in support of this measure from the Clarity Project; Aloha Integrative Mental Health; Centered Hawaii, LLC; Michal Cohen, LCSW; Reason for Hope; and numerous individuals.
Your Committee received written comments on this measure from the Attorney General, Department of Budget and Finance, and Department of Health.
Your Committee finds that the special fund established and research supported by this measure will help facilitate patient access to innovative mental health treatments.
As affirmed by the record of votes of the members of your Committee on Ways and Means that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1042, S.D. 1, and recommends that it pass Third Reading.
Respectfully submitted on behalf of the members of the Committee on Ways and Means,
|
|
|
________________________________ DONOVAN M. DELA CRUZ, Chair |
|
|
|
|
STAND. COM. REP. NO. 625
Honolulu, Hawaii
RE: S.B. No. 1042
S.D. 1
Honorable Ronald D. Kouchi
President of the Senate
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Sir:
Your Committee on Health and Human Services, to which was referred S.B. No. 1042 entitled:
"A BILL FOR AN ACT RELATING TO MENTAL HEALTH,"
begs leave to report as follows:
The purpose and intent of this measure is to:
(1) Establish and appropriate funds for a Mental Health Emerging Therapies Special Fund to be administered by the Department of Health; and
(2) Require annual reports to the Legislature.
Your Committee received testimony in support of this measure from the Clarity Project, Veteran Mental Health Leadership Coalition, Reason for Hope, Transcend Integration, Honolulu Psychotherapy, Beyond Mental Health, Center for Healing & Transformation LLC, Aloha Integrative Mental Health, Veterans Exploring Treatment Solutions, Reason for Hope, Aloha Green Apothecary, and numerous individuals.
Your Committee received comments on this measure from the Office of the Governor, Department of the Attorney General, Department of Budget and Finance, and Department of Health.
Your Committee finds that mental health conditions, including depression, anxiety, schizophrenia, bipolar disorder, and post-traumatic stress disorder, are widespread and affecting millions worldwide and many in the State's community. Your Committee further finds that while traditional first-line treatment modalities have significantly improved outcomes, they often fall short for those experiencing treatment resistant symptoms, which can lead to great personal, social, and economic impact and consequences. Your Committee additionally finds that emerging therapies for the treatment of behavioral health conditions, including those that have received breakthrough therapy designation, provide new pathways and have a potential for more rapid and effective treatment. This measure supports the continued research, education, and preparation for adaptation to add to available clinical approaches to reduce suffering and improve well-being for patients in the State.
Your Committee has amended this measure by:
(1) Inserting an effective date of December 31, 2050, to encourage further discussion; and
(2) Making technical, nonsubstantive amendments for the purposes of clarity and consistency.
As affirmed by the record of votes of the members of your Committee on Health and Human Services that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1042, as amended herein, and recommends that it pass Second Reading in the form attached hereto as S.B. No. 1042, S.D. 1, and be referred to your Committee on Ways and Means.
Respectfully submitted on behalf of the members of the Committee on Health and Human Services,
|
|
|
________________________________ JOY A. SAN BUENAVENTURA, Chair |
|
|
|
|
|
Date
|
Testimony PDF
|
|---|---|
| Apr 2, 2025 | SB1042_HD1_TESTIMONY_FIN_04-02-25_.PDF |
| Mar 14, 2025 | SB1042_SD1_TESTIMONY_HLT_03-14-25_.PDF |
| Feb 19, 2025 | SB1042_SD1_TESTIMONY_WAM_02-19-25_.PDF |
| Feb 12, 2025 | SB1042_TESTIMONY_HHS_02-12-25_.PDF |
Discussed in Hearing
1MIN
Conference Committee
55MIN
House Standing Committee on Finance
29MIN
House Standing Committee on Health
19MIN
Senate Standing Committee on Health and Human Services
19MIN
Senate Standing Committee on Higher Education
24SEC
Senate Standing Committee on Health and Human Services
24SEC
Senate Standing Committee on Higher Education
10SEC
Senate Standing Committee on Health and Human Services
Bill Author
